This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E72.2 | Special Copayment Reduction: V117 |
| B. Synonyms | Citrullinemia type I, ASS1 deficiency (Argininosuccinate synthetase deficiency), hypercitrullinemia, Classic citrullinemia |
| C. Adult onset | Likelihood of first diagnosis in adulthood: low (classic form) — classic citrullinemia type I mostly presents in the neonatal period, but in patients with mild residual ASS1 activity, acute hyperammonemia may first present in adulthood. Citrullinemia type II (citrin deficiency) characteristically presents in adulthood and is classified separately. |
| 1. History | 1962 McMurray et al. first described citrullinemia → ASS1 gene cloning (1980s) → inclusion in tandem MS/MS newborn screening → elucidation of the citrin deficiency (type II) mechanism (2001 Kobayashi). |
| 2. Causes | Pathogenic variants in the ASS1 gene (9q34.1) → block of urea cycle step 3 (citrulline + aspartate → argininosuccinate) → marked citrulline accumulation + hyperammonemia. Autosomal recessive. Citrullinemia type II is a separate disease due to SLC25A13 (citrin) deficiency. |
| 3. Genetics | ASS1 gene (9q34.1): 16 exons. More than 100 variants. The c.1168G>A (p.Gly390Arg) variant is frequently reported especially in East Asia, including Japan·Korea. Autosomal recessive. Citrin (SLC25A13) deficiency is a distinct gene defect that is relatively common in East Asia. |
| 4. General epidemiology | Citrullinemia type I (ASS1 deficiency): about 1 in 57,000~250,000. Citrullinemia type II (citrin deficiency): about 1 in 17,000~230,000 in East Asia (more common in Japan·Korea). |
| 5. Pathophysiology | ASS1 deficiency → citrulline cannot be converted to argininosuccinate → marked citrulline accumulation → arginine deficiency → blocked urea synthesis → hyperammonemia. Toxicity of citrulline itself is under study. |
| 6. Symptoms | Severe neonatal form: lethargy, feeding refusal, seizures, coma (hyperammonemic encephalopathy) 24~72 hours after birth. Mild/late-onset form: recurrent vomiting, failure to thrive, cognitive impairment. Citrullinemia type II: episodes resembling hepatic encephalopathy in adulthood, preference for protein and fat. |
| 7. Signs | Markedly elevated plasma citrulline (> 1,000 μmol/L, type I). Elevated blood ammonia. Mild~moderate elevation of urine orotic acid. Low plasma arginine. |
| 8. Screening | Newborn tandem MS/MS: markedly elevated citrulline (type I > 300 μmol/L or higher). Type II (citrin deficiency) can also be detected on screening by elevated neonatal citrulline, but is mainly discovered through NICCD findings. |
| 9. Diagnosis | Plasma amino acids (markedly elevated citrulline, argininosuccinate undetectable), blood ammonia, urine orotic acid, ASS1 enzyme activity (liver, skin fibroblasts), ASS1 gene NGS. SLC25A13 gene (to differentiate type II). |
| 10. Treatment | Acute hyperammonemia: standard emergency care (stop protein, high-calorie IV, nitrogen scavengers, hemodialysis). Chronic: low-protein diet, arginine supplementation, nitrogen scavengers (benzoate/phenylbutyrate). Liver transplantation (curative treatment). Citrullinemia type II: high-protein·high-fat diet, carbohydrate restriction, sodium pyruvate, liver transplantation. |
| 11. Prognosis | Severe neonatal form (type I): survival possible with early treatment but risk of neurological damage. Ammonia normalizes after liver transplantation. Citrullinemia type II: prognosis improved by liver transplantation. Untreated, recurrent encephalopathy causes neurological damage. |
| 12. Prevention | Early diagnosis by newborn screening. Familiarity with emergency care protocols. Genetic counseling and family screening. Citrullinemia type II: avoid high-carbohydrate·low-fat diets, limit alcohol. |
| 13. References | Häberle J et al. J Inherit Metab Dis. 2019, and 9 others |
Citrullinemia was recognized as a clinical disease in 1962 when McMurray, Ruchi, and colleagues in the United States first described a patient with excessive urinary citrulline excretion, markedly elevated plasma citrulline, and intellectual disability. In this patient, previously unseen large amounts of citrulline were detected in the urine, accompanied by elevated blood ammonia. Subsequently, through the 1970s~1980s, deficiency of argininosuccinate synthetase (ASS1) was biochemically confirmed as the causative enzyme, and citrullinemia became established as one of the urea cycle enzyme deficiency disorders.
The ASS1 gene is located on the long arm of chromosome 9 (9q34.1) and was cloned in the late 1980s, enabling molecular biological research. More than 100 pathogenic variants have since been reported, and variant patterns relatively common in Asians have been identified. In Japan and Korea, the c.1168G>A (p.Gly390Arg) variant is reported relatively frequently in patients with citrullinemia type I.
An important historical development related to citrullinemia was the elucidation of the independent mechanism of citrullinemia type II. In 2001, Kobayashi et al. showed that variants in the SLC25A13 gene (encoding the protein citrin) were the cause in a group of patients in East Asia, particularly Japan, with adult-onset symptoms resembling hepatic encephalopathy. Citrin is an aspartate-glutamate carrier of the inner mitochondrial membrane; in citrin deficiency, insufficient aspartate supply blocks the ASS1 reaction and citrulline accumulates. Because this form results from a substrate supply defect rather than a gene defect of ASS1 itself, it is classified as a distinct type (type II). It presents in the neonatal period as NICCD (neonatal intrahepatic cholestasis caused by citrin deficiency) and in adulthood as CTLN2 (adult-onset type II citrullinemia). This disease is clinically important particularly in Japan and Korea.
As tandem mass spectrometry (MS/MS) newborn screening spread in the 2000s, citrullinemia type I became detectable early through markedly elevated neonatal blood citrulline. With early treatment, the neurodevelopmental protective effect of presymptomatic treatment was confirmed, and mortality from severe neonatal hyperammonemia decreased.
Citrullinemia type I (CTLN1) is an autosomal recessive genetic disorder caused by deficiency of argininosuccinate synthetase (ASS1) due to pathogenic variants in the ASS1 gene (9q34.1). ASS1 is the third enzyme of the urea cycle and catalyzes the synthesis of argininosuccinate from citrulline and aspartate. When this reaction is blocked, citrulline accumulates markedly in plasma and urine, and because argininosuccinate is not produced, both arginine synthesis and urea synthesis are blocked, resulting in hyperammonemia.
ASS1 is expressed mainly in the liver and participates in urea synthesis, but it is also expressed in vascular endothelial cells, neurons, and other cells, where it contributes to the arginine supply for the NO synthesis pathway. Some studies suggest that abnormalities of the NO synthesis pathway may also contribute to the pathophysiology of citrullinemia type I, but this is not as pronounced as in argininosuccinic aciduria (ASL deficiency).
Citrullinemia type II (CTLN2) is an autosomal recessive disorder caused by deficiency of the aspartate-glutamate carrier of the inner mitochondrial membrane (citrin) due to variants in the SLC25A13 gene (7q21.3). In citrin deficiency, aspartate is not transported sufficiently from the mitochondria to the cytoplasm, so the supply of aspartate, the substrate of ASS1, becomes insufficient; as a result, citrulline accumulates and urea synthesis is impaired. Citrin deficiency presents as NICCD (neonatal intrahepatic cholestasis) in the neonatal period and as CTLN2 in adulthood. In Korea and Japan, the SLC25A13 c.IVS16ins3kb and c.851del4 variants are reported relatively frequently. This file focuses on type I (ASS1 deficiency) and mentions the main features of type II.
The ASS1 gene is located on the long arm of chromosome 9 (9q34.1) and consists of 16 exons. The mature ASS1 protein is 412 amino acids long and functions as a homotetramer. More than 100 pathogenic variants have been reported to date, including missense, nonsense, and splicing variants and small deletions/insertions. Phenotypic severity correlates with residual enzyme activity: variants causing complete deficiency are associated with the severe neonatal form, and some missense variants with mild~moderate phenotypes.
One of the main ASS1 variants reported in East Asia, especially Japan and Korea, is c.1168G>A (p.Gly390Arg). This variant affects trimer/tetramer formation of the ASS1 enzyme and markedly reduces enzyme activity. There are reports that this variant is found at considerable frequency in Korean patients with citrullinemia type I. Inheritance is autosomal recessive; each parent is a heterozygous carrier, and each child has a 25% risk of being affected. De novo variants are rare. After molecular genetic confirmation, prenatal diagnosis (CVS, amniocentesis) or preimplantation genetic testing (PGT) is possible.
Citrullinemia type II (SLC25A13 deficiency): the SLC25A13 gene is located on the long arm of chromosome 7 (7q21.3) and is reported relatively frequently in Korea and Japan. Major variants include c.IVS16ins3kb (3 kb insertion in intron 16), c.851del4 (4-base deletion), and c.1638ins23. In particular, c.IVS16ins3kb and c.851del4 account for a considerable proportion of the known variants in Asian patients. Targeted genetic testing for these two variants allows relatively rapid molecular diagnosis in Asian patients.
The incidence of citrullinemia type I (ASS1 deficiency) is estimated from tandem MS/MS newborn screening data at about 1 in 57,000~250,000 births. US newborn screening data report a frequency of about 1 in 130,000, and similar frequencies are reported in some European countries. Citrullinemia type I is one of the UCDs detected relatively effectively on tandem MS/MS screening through markedly elevated blood citrulline. However, differentiation is needed from mild variants with lower citrulline elevation than ASS1 deficiency and from the neonatal form of citrullinemia type II (NICCD).
The frequency of citrullinemia type II (citrin deficiency) is particularly high in East Asia. In Japan, the frequency of CTLN2 is reported at about 1 in 17,000~230,000, and a similar frequency is estimated in Korea. Neonatal NICCD is one of the important causes of cholestasis in neonatal intensive care settings in Japan and Korea. CTLN2 (adult-type citrullinemia type II) is one of the most common hereditary causes of adult-onset hyperammonemia in Japan, and a similar pattern is observed in Korea.
In Korea, citrullinemia is managed under code E72.2 under the rare disease registration criteria and is eligible for Special Copayment Reduction V117. Since the expansion of newborn screening, detection of type I in the neonatal period has increased. Citrullinemia shows no difference in frequency by sex (autosomal recessive) and occurs in all ethnic groups, but has an ethnic specificity in that type II due to SLC25A13 variants is particularly common in East Asia.
The core pathophysiology of citrullinemia type I (ASS1 deficiency) is citrulline accumulation and hyperammonemia due to a block at step 3 of the urea cycle.
Molecular mechanism of ASS1 deficiency: in step 3 of the urea cycle, citrulline and aspartate are converted by ASS1 to argininosuccinic acid. When ASS1 is deficient, this reaction is blocked and citrulline accumulates in plasma and tissues. The normal plasma concentration of citrulline is usually 20~40 μmol/L, but in CTLN1 it rises to hundreds~thousands of μmol/L. At the same time, because argininosuccinate is not produced, arginine is not supplied, and the final step of the urea cycle (arginine → urea + ornithine) cannot proceed either. This double block severely impairs ammonia excretion, resulting in hyperammonemia.
Pathology of citrulline itself: the toxic mechanism of excessive citrulline accumulation has not been fully elucidated to date. Some studies provide experimental evidence that high citrulline itself is toxic to neurons, but clinically, ammonia toxicity is regarded as the main cause of neurological damage. Reduced NO synthesis due to arginine deficiency may also contribute to the pathophysiology.
Mechanism of citrullinemia type II (citrin deficiency): citrin, in the inner mitochondrial membrane, exchanges aspartate from the mitochondria to the cytoplasm and glutamate from the cytoplasm to the mitochondria. When citrin is deficient, cytoplasmic aspartate decreases and the substrate for ASS1 becomes insufficient. Therefore, urea synthesis is impaired even though ASS1 itself is normal. At the same time, an NADH/NAD⁺ imbalance alters the cytoplasmic redox state, affecting various metabolic pathways such as gluconeogenesis, glycolysis, and fatty acid oxidation. This is the pathophysiological background of the distinctive appetite pattern in type II patients, who avoid high-carbohydrate·low-fat diets and prefer protein/fat-based diets.
The clinical symptoms of citrullinemia differ distinctly between type I (ASS1 deficiency) and type II (citrin deficiency).
Citrullinemia type I — severe neonatal form: with complete ASS1 deficiency, hyperammonemic encephalopathy develops within 24~72 hours after birth. Feeding refusal, lethargy, hypothermia or temperature instability, vomiting, hyperpnea (Kussmaul breathing), seizures, and coma progress sequentially. Untreated, it can deteriorate rapidly and lead to death. Because clinical differentiation from neonatal sepsis and neonatal encephalopathy is difficult, blood ammonia should be measured immediately in any neonatal lethargy of unknown cause.
Citrullinemia type I — mild/late-onset form: when residual ASS1 activity remains, the neonatal period may pass uneventfully, but acute hyperammonemia is triggered under metabolic stress such as infection, a high-protein diet, or surgery. Chronic symptoms include failure to thrive, protein aversion, recurrent vomiting, and cognitive impairment. Rarely, cases have been reported that remain asymptomatic until adulthood before first presenting.
Citrullinemia type II — neonatal form (NICCD): in the neonatal period, cholestatic jaundice with predominantly elevated direct bilirubin, hepatomegaly, failure to thrive, hypoglycemia, hypoproteinemia, and similar findings appear. Most improve spontaneously before age 1, but some later progress to the adult form (CTLN2). During this period, high-carbohydrate diets and dairy products may worsen the metabolic derangement.
Citrullinemia type II — adult form (CTLN2): mainly in adults (20s~50s), intermittent episodes of hyperammonemic encephalopathy (nocturnal behavioral abnormalities, disorientation, coma), abnormal behavior, memory decline, and seizures occur. Characteristically, patients show an appetite pattern of preferring protein and fat and avoiding carbohydrates (rice, noodles, bread). Hepatic steatosis is sometimes present.
The main laboratory findings and physical signs of citrullinemia are as follows.
Markedly elevated plasma citrulline: in citrullinemia type I, plasma citrulline is usually markedly elevated to 1,000 μmol/L or higher (normal < 40 μmol/L). This is much higher than in argininosuccinic aciduria (citrulline 100~300 μmol/L), another disease under the same code (E72.2), allowing biochemical differentiation of the two diseases. Citrulline is also elevated in the neonatal form of citrullinemia type II (NICCD), but in the adult form (CTLN2) citrulline may be only normal~mildly elevated between attacks.
Argininosuccinate undetectable: in citrullinemia type I, the absence of detectable argininosuccinate in plasma and urine is the key finding differentiating it from argininosuccinic aciduria (ASL deficiency). In argininosuccinic aciduria, argininosuccinate is detected.
Blood ammonia: markedly elevated in the acute phase or during metabolic stress (hundreds~thousands of μmol/L in the severe neonatal form). Normal~mildly elevated in the chronic phase.
Urine orotic acid: mild~moderate elevation (lower than in OTC deficiency). Because of the ASS1 block, some carbamoyl phosphate is diverted to the pyrimidine pathway, increasing orotic acid.
Physical findings: in acute hyperammonemic encephalopathy, decreased consciousness, seizures, hyperpnea. In the chronic form, failure to thrive, hepatomegaly. In citrullinemia type II (NICCD), jaundice and increased liver echogenicity on abdominal ultrasound.
Citrullinemia type I is detected relatively effectively on the tandem MS/MS newborn screening panel through markedly elevated blood citrulline.
Newborn tandem MS/MS screening: if blood citrulline on dried blood spot (DBS) is elevated to 300 μmol/L or higher (usually > 1,000 μmol/L in citrullinemia type I), citrullinemia type I or citrullinemia type II (NICCD) is suspected. Because citrulline is also elevated to 100~300 μmol/L in argininosuccinic aciduria (ASL deficiency), differentiation by citrulline level and the presence of argininosuccinate is needed. Citrulline is included in the Korean newborn screening program, so type I can be detected.
Screening for citrullinemia type II: elevated citrulline can occur in the neonatal form (NICCD), so it may be detected on tandem MS/MS screening. The adult form (CTLN2) is not a target of newborn screening, so in adults with unexplained episodes resembling hepatic encephalopathy or an unusual appetite pattern (carbohydrate avoidance, protein/fat preference), SLC25A13 genetic testing is needed. When CTLN2 is suspected in Korea and Japan, targeted testing for the known common SLC25A13 variants (c.IVS16ins3kb, c.851del4) increases diagnostic efficiency.
Confirmatory tests: quantitative plasma amino acids (markedly elevated citrulline, argininosuccinate undetectable), blood ammonia, urine organic acids (orotic acid). Enzyme activity (ASS1, skin fibroblasts or liver) and ASS1 or SLC25A13 gene NGS.
Citrullinemia is confirmed by biochemical findings and molecular genetic confirmation.
Plasma amino acid chromatography: if plasma citrulline is markedly elevated (> 300 μmol/L, usually 1,000 μmol/L or higher in type I) and argininosuccinate is not detected, a presumptive diagnosis of citrullinemia type I is made. Differentiation from argininosuccinic aciduria: in argininosuccinic aciduria, citrulline is 100~300 μmol/L and argininosuccinate is detected in plasma and urine.
Blood ammonia: elevation confirmed in the acute phase and during periods of metabolic stress.
Urine orotic acid: moderate elevation. Orotic acid is elevated on urine organic acid analysis but tends to be lower than in OTC deficiency.
Enzyme activity measurement: ASS1 activity is measured in liver tissue biopsy or cultured skin fibroblasts. However, because tandem MS/MS and genetic testing are the main means of diagnosis, enzyme measurement is not always necessary.
Molecular genetic confirmation: pathogenic variants are identified by NGS of the ASS1 gene (type I) or SLC25A13 gene (type II) panel. Identification of a variant confirms the diagnosis and is used for family counseling and prenatal diagnosis. In Koreans, targeted testing for specific variants such as SLC25A13 c.IVS16ins3kb allows rapid diagnosis.
Additional tests: liver function tests (AST, ALT, bilirubin), abdominal ultrasound (hepatomegaly, steatosis), brain MRI (assessment of neurological damage), neurodevelopmental testing.
The treatment principles for citrullinemia type I (ASS1 deficiency) and type II (citrin deficiency) differ in part.
Citrullinemia type I — emergency treatment of acute hyperammonemia: the same emergency protocol as for other UCDs is applied. ① Immediately stop protein intake (24~48 hours), ② high-calorie intravenous supply (glucose + lipids), ③ intravenous nitrogen scavengers (sodium benzoate + sodium phenylacetate), ④ intravenous arginine (a conditionally essential amino acid), ⑤ in severe cases, hemodialysis or continuous renal replacement therapy (CRRT).
Citrullinemia type I — long-term chronic treatment: low-protein diet (minimum age-specific requirements), amino acid formula supplementation, oral arginine supplementation (arginine is a conditionally essential amino acid in type I), oral nitrogen scavengers (glycerol phenylbutyrate or sodium phenylbutyrate). Education on emergency care protocols and carrying a medical alert card.
Liver transplantation: in citrullinemia type I, liver transplantation curatively corrects the urea cycle and resolves hyperammonemia. Liver transplantation is recommended for repeated hyperammonemic episodes, poor dietary control, or progressive neurological damage. After transplantation, protein restriction becomes unnecessary and quality of life improves.
Treatment of citrullinemia type II (NICCD): whey protein-based formula or lactose-free formula is used rather than breastfeeding, and the carbohydrate proportion is lowered. In childhood, a high-protein·high-fat diet is maintained. Sodium pyruvate or medium-chain triglycerides (MCT) help some patients. In most cases, intrahepatic cholestasis improves spontaneously before age 1.
Treatment of citrullinemia type II (CTLN2): carbohydrate restriction and a protein·fat-based diet (consistent with the patient's natural food preferences). Emergency care during episodes of acute hyperammonemic encephalopathy. Sodium pyruvate or MCT supplementation. Curative treatment is liver transplantation, after which prognosis improves markedly. In CTLN2, caution is needed because high-carbohydrate intravenous infusion (glucose solution) can worsen the metabolic derangement.
The prognosis of citrullinemia differs between type I and type II and depends greatly on the timing of treatment initiation and the severity·frequency of hyperammonemic episodes.
Prognosis of citrullinemia type I: survival has improved greatly with early diagnosis and treatment through newborn screening. Cohort studies have shown that cognitive outcomes in patients who received early treatment are markedly better than in untreated groups. However, even with early treatment, cognitive impairment, learning disabilities, and behavioral problems are reported in about 30~60%. The intensity and duration of hyperammonemic episodes are the most important determinants of neurodevelopmental prognosis.
After liver transplantation, ammonia-related complications resolve completely. If there was no neurological damage before transplantation, normal development is expected after transplantation. The transplant success rate is excellent, at over 95%.
Prognosis of citrullinemia type II: in most cases of NICCD, intrahepatic cholestasis improves spontaneously before age 1, but some show growth retardation, delayed intellectual development, and later progression to CTLN2. In CTLN2, cognitive function may decline progressively due to repeated episodes of hyperammonemic encephalopathy, and prognosis improves greatly after liver transplantation. Because recovery from neurological damage that occurred before transplantation is limited, early liver transplantation is recommended.
Prevention of citrullinemia consists of early diagnosis by newborn screening, metabolic management to prevent complications, and family genetic counseling.
Early diagnosis by newborn screening: when citrulline is markedly elevated on tandem MS/MS newborn screening, immediate confirmatory testing and initiation of treatment are the most effective preventive strategy to minimize neurological damage from severe neonatal hyperammonemia. Citrulline is included in the Korean newborn screening program.
Emergency care protocol and education: all patients with citrullinemia type I and their caregivers must be familiar with the emergency care protocol for metabolic stress situations such as fever, infection, and vomiting. Carrying a medical alert card, sharing contact information for the treating metabolic physician, and guidance on immediate blood ammonia measurement in the emergency department are needed.
Prevention for citrullinemia type II: patients with citrin deficiency (type II) and caregivers of NICCD patients should avoid carbohydrate-excess diets (especially high-carbohydrate intravenous fluids). Adult CTLN2 patients should avoid alcohol intake, high-carbohydrate meals, and fasting, and should go to the emergency department immediately if an acute encephalopathy episode occurs.
Genetic counseling and family screening: in type I (autosomal recessive), both parents of a patient are carriers and siblings have a 25% risk of being affected. In subsequent pregnancies, implantation of an affected fetus can be avoided through prenatal diagnosis (CVS, amniocentesis) or PGT. In type II, carrier status for SLC25A13 variants common in Koreans·Japanese is checked by family testing.
Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. J Inherit Metab Dis. 2019;42(6):1192-1230. DOI: 10.1002/jimd.12100. PMID: 30982989.
Kobayashi K, Sinasac DS, Iijima M, et al. The gene mutated in adult-onset type II citrullinaemia encodes a putative mitochondrial carrier protein. Nat Genet. 1999;22(2):159-163. DOI: 10.1038/9667. PMID: 10369257.
Nagata N, Matsuda I, Oyanagi K. Estimated frequency of urea cycle enzymopathies in Japan. Am J Med Genet. 1991;39(2):228-229. DOI: 10.1002/ajmg.1320390224. PMID: 1867280.
Tuchman M, Lee B, Lichter-Konecki U, et al. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab. 2008;94(4):397-402. DOI: 10.1016/j.ymgme.2008.05.004. PMID: 18579413.
Saheki T, Kobayashi K, Iijima M, et al. Metabolic derangements in deficiency of citrin, a liver-type mitochondrial aspartate-glutamate carrier. Metab Brain Dis. 2002;17(4):335-346. PMID: 12602513.
Lim JS, Tan ES, John CM, et al. Inborn error of metabolism (IEM) causing acute liver failure in neonates and infants — early diagnosis is the key. J Pediatr Surg. 2017;52(11):1848-1852. DOI: 10.1016/j.jpedsurg.2017.08.053. PMID: 28918868.
Kim JH, Lee BH, Kim YM, et al. Novel SLC25A13 mutations in Korean patients with citrin deficiency. J Hum Genet. 2012;57(11):753-756. DOI: 10.1038/jhg.2012.98. PMID: 22895513.
Wilcken B, Wiley V. Newborn screening. Pathology. 2008;40(2):104-115. DOI: 10.1080/00313020701813743. PMID: 18203053.
Enns GM, Berry SA, Berry GT, et al. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med. 2007;356(22):2282-2292. DOI: 10.1056/NEJMoa066596. PMID: 17538087.
Lee HJ, Yoo HW. Clinical and biochemical features of citrullinemia detected by newborn screening in Korea. J Korean Med Sci. 2008;23(4):639-644. DOI: 10.3346/jkms.2008.23.4.639. PMID: 18756053.